Essential Hypertension clinical trials

Explore recruiting essential hypertension clinical trials.

Recruiting essential hypertension studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Essential Hypertension trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A single-dose, randomized, two-period, two-sequence, crossover comparative bioavailability study on formulations containing ramipril, amlodipine and indapamide in combination product versus Triatec® 10 mg capsules (Sanofi - Produtos Farmacêuticos, Lda., Portugal), containing ramipril, Norvasc® 10 mg, tablets (Upjohn EESV, the Netherlands), containing amlodipine and Natrilix® 2.5 mg film-coated tablets (Les Laboratoires Servier, France), containing indapamide co-administered together as reference in healthy male and female volunteers under fasting conditions.

Czechia

Human Pharmacology (Phase I)- Bioequivalence Study EU CTIS Study details

Multi-Omics to predict the blood pressure response to antihypertensives

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

Randomized, open-label, replicated single-dose, 4-period, 2-sequence crossover study to assess the comparative bioavailability of test product Amlodipine/Valsartan/Hydrochlorothiazide 10 mg/160 mg/12.5 mg film-coated tablets to reference product Exforge HCT 10 mg/160 mg/12.5 mg film-coated tablets in healthy male and female subjects under fasting conditions.

Czechia

Human Pharmacology (Phase I)- Bioequivalence Study EU CTIS Study details

Essential Hypertension trials by city

Essential Hypertension in Toronto Essential Hypertension in Vancouver Essential Hypertension in Montreal Essential Hypertension in Calgary Essential Hypertension in Edmonton Essential Hypertension in Ottawa Essential Hypertension in Winnipeg Essential Hypertension in Quebec City Essential Hypertension in Hamilton Essential Hypertension in Kitchener Essential Hypertension in London Essential Hypertension in Halifax Essential Hypertension in New York Essential Hypertension in Los Angeles Essential Hypertension in Chicago Essential Hypertension in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease